Latest report from Public Health Ontario on adverse events after vaccinationÑ
Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to July 3, 2022
publichealthontario.ca
Highlights
There are a total of 21,004 AEFI reports received following 33,028,686 doses of COVID-19 vaccines administered in Ontario to date with a reporting rate of 63.6 per 100,000 doses administered (0.06% of all doses administered)
This represents an increase of 137 AEFI reports compared to the previous report
Of the total 21,004 AEFI reports received to date:
19,825 AEFI reports are non-serious (94.4% of total AEFI reports)
1,179 AEFI reports meet the serious definition (5.6% of total AEFI reports)
The most commonly reported adverse events are other severe or unusual events and allergic
skin reactions, reported in 27.8% and 22.5% of the total AEFI reports, respectively
1,601 reports include a COVID-19 vaccine-specific adverse event of special interest, in which 708
reports also meet the serious definition (see Adverse events of special interest section for more
information)
21 reports of thrombosis with thrombocytopenia syndrome (TTS) after receipt of AstraZeneca
Vaxzevria/COVISHIELD COVID-19 vaccine, of which 16 are vaccine-induced immune thrombotic
thrombocytopenia (VITT) (see TTS/VITT section for more information)
775 reports of myocarditis or pericarditis after receipt of mRNA vaccine (see Myocarditis/pericarditis section for more information)
Ontario is continuing to monitor all AEFIs reported following receipt of COVID-19 immunization in
collaboration with its partners. |
